EMA Backs Generic Versions of AstraZeneca’s Symbicort
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. won the backing of a European Medicines Agency committee for a new version of lung therapy Symbicort, paving the way for competition to one of AstraZeneca Plc’s best-selling drugs.
The generic formulation of budesonide and formoterol, to be marketed as DuoResp Spiromax and BiResp Spiromax, should be approved for the treatment of asthma and chronic obstructive pulmonary disease, the London-based EMA’s Committee for Medicinal Products for Human Use, or CHMP, said today in a statement.